Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Exploration of Targeted Anti-tumor Therapy is Scopus-indexed (Q2, CiteScore 5.4), DOAJ. Published by Open Exploration Publishing Inc.
Checked against the index lists dated .
ISSN 2692-3114Verify ISSN ↗
Publisher: Open Exploration Publishing Inc
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 140 / 428 | 67th | Q2 |
| Cancer Research | 115 / 233 | 50th | Q2 |
Not listed in: Web of Science, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2020–present, best quartile Q2, CiteScore 5.4.
Exploration of Targeted Anti-tumor Therapy is Q2 in Oncology (rank 140 of 428) and Q2 in Cancer Research (rank 115 of 233), by CiteScore 2025.
Exploration of Targeted Anti-tumor Therapy is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 5.4, quartile Q2, 67th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.883, quartile Q2, with an H-index of 21.
Exploration of Targeted Anti-tumor Therapy is published by Open Exploration Publishing Inc. Its ISSN is 2692-3114.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Yes — it is an open-access journal, listed in DOAJ.
Exploration of Targeted Anti-tumor Therapy has an h-index of 27 and a 2-year mean of 5.72 citations per paper (OpenAlex). Its Scopus CiteScore is 5.4, quartile Q2. On 2-year citations it ranks #43 of 424 Scopus journals in Oncology.
Exploration of Targeted Anti-tumor Therapy published 71 papers in 2025; its busiest recent year was 2024 with 85. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 96 research articles (2025–2026), authors are most often from United States (23.7%), Italy (9.7%) and India (9.5%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (4.9 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.